Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection

被引：18

作者：

Maples, HD

Stowe, CD

Saccente, SL

Jacobs, RF

机构：

[1] Univ Arkansas Med Sci, Coll Pharm, Dept Pediat, Little Rock, AR 72205 USA

[2] Arkansas Childrens Hosp, Little Rock, AR 72202 USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2003年 / 22卷 / 11期

关键词：

voriconazole; skin infection; Trichosporon beigelii; infant;

D O I：

10.1097/01.inf.0000095167.38306.76

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A neutropenic 10-week-old with hemophagocytic lymphohistiocytosis developed a cutaneous Trichosporon beigelii infection that was treated for 78 days with voriconazole. A starting dose of 6 mg/kg/ dose every 12 h was initiated, and serum concentrations were obtained. The infection resolved; however, the serum concentrations obtained while receiving and not receiving phenobarbital would be considered subtherapeutic for the treatment of invasive fungal infection.

引用

页码：1022 / 1024

页数：3

共 10 条

[1] Andersson T, 2000, AM J GASTROENTEROL, V95, P3101
[2] Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia
Fournier, S
Pavageau, W
Feuillhade, M
Deplus, S
Zagdanski, AM
Verola, O
Dombret, H
Molina, JM
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (12) : 892 - 896
[3] Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
Jabado, N
Casanova, JL
Haddad, E
Dulieu, F
Fournet, JC
Dupont, B
Fischer, A
Hennequin, C
Blanche, S
[J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (06) : 1437 - 1441
[4] Voriconazole: A new triazole antifungal agent
Johnson, LB
Kauffman, CA
[J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) : 630 - 637
[5] In vitro antifungal susceptibilities of Trichosporon species
Paphitou, NI
Ostrosky-Zeichner, L
Paetznick, VL
Rodriguez, JR
Chen, E
Rex, JH
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1144 - 1146
[6] Development and validation of a high-performance liquid chromatography assay for voriconazole
Pennick, GJ
Clark, M
Sutton, DA
Rinaldi, MG
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2348 - 2350
[7] Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
Purkins, L
Wood, N
Ghahramani, P
Greenhalgh, K
Allen, MJ
Kleinermans, D
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) : 2546 - 2553
[8] Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease
van't Hek, LG
Verweij, PE
Weemaes, CM
van Dalen, R
Yntema, JB
Meis, JF
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 157 (05) : 1694 - 1696
[9] Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children
Walsh, TJ
Lutsar, I
Driscoll, T
Dupont, B
Roden, M
Ghahramani, P
Hodges, M
Groll, AH
Perfect, JR
[J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (03) : 240 - 248
[10] WALSH TJ, 2001, 41 INT C ANT AG CHEM, P2

← 1 →